← All indications
Gonorrhea
Acute infectious disease characterized by primary invasion of the urogenital tract. The etiologic agent, NEISSERIA GONORRHOEAE, was isolated by Neisser in 1879.
Drugs by status
Approved for this indication (14)
Phase 3 trials (11)
Phase 2 trials (5)
Phase 1 trials (6)
Other trials (1)
Organizations
Organization Involved with Phase 4 Indications (20)
- Mayne Pharma
- Xiangbei Welman Pharmaceutical Co., Ltd
- National Institute of Allergy and Infectious Diseases (NIAID)
- University of Washington
- Kenya Medical Research Institute
- Fujian Medical University
- Laval University
- University of California, San Francisco
- University of Montreal
- University of North Carolina at Chapel Hill
- University of Sherbrooke
- City of San Francisco
- Kenya National AIDS & STI Control Programme
- People's Hospital of Quzhou
- Yanbian University
- Government of Benin
- Shanghai Dermatology Hospital
- Hangzhou Third Hospital
- The Central Hospital of Shanghai Minhang District
- People's Hospital of Shanghai Pudong New Area
Organization Involved with Phase 3 Indications (16)
- Cempra Inc
- Evofem Inc.
- Endo Pharmaceuticals
- GlaxoSmithKline
- FHI 360
- Medical Research Council
- University of Melbourne
- Lagos State University
- University of Amsterdam
- Melinta Therapeutics
- University of New South Wales
- Griffith University
- University of Port Harcourt
- Government of Netherlands
- Global Antibiotics Research and Development Partnership
- Institute for Glycomics, Griffith University, Queensland, Australia
Organization Involved with Phase 2 Indications (13)
- Alopexx
- Population Council
- Medical Research Council, South Africa
- University of Limpopo
- University of Cape Town
- University of Alabama, Birmingham
- Bill and Melinda Gates Foundation
- Chiangrai Prachanukroh Hospital
- United States Agency for International Development
- Chiang Rai District Health Office
- National Center for Infectious Diseases
- Government of Thailand
- Centers for Disease Control and Prevention (CDC)
Organization Involved with Phase 1 Indications (6)
Organization Involved with Other Experimental Indications (2)